Provider review
Vyvron Review: It Tells You Exactly What It Is, and Nothing About What Is In the Vial
Vyvron is refreshingly clear about one thing and silent about another, and the two are related. It states plainly that it is "a marketing and customer-acquisition platform", not a provider or a pharmacy, and names the medical group that treats you. Then it sells a sermorelin program at $189 every four weeks, rising to $229 — for a peptide whose newest randomized trial anywhere was published in 2005.
Some links on this site are affiliate links, and we may earn a commission. How we’re paid
Visit VyvronOf Vyvron’s 5 dated product claims documented below, 1 is consistent with the cited evidence. Comparable upfront pricing is not established here. A matching claim does not mean the compounded product was tested or FDA-approved.
Vyvron is honest about its structure and silent about its substance. It will tell you it is a marketing platform, name the medical group that will treat you, label its programs as compounded and not FDA-approved, and refuse to claim its compounded GLP-1s are equivalent to the branded ones. Those are real virtues and they are rarer than they should be. But it sells three peptide and vitamin products into a longevity program where the evidence ranges from thin to absent — sermorelin's newest randomized trial is from 2005, injectable NAD+ has one, and the B12-MIC blend has none — and it publishes nothing at all about who tests those preparations, for what, or to what standard. Vyvron has written a guide on how to verify a legitimate online provider. On the question its own guide would ask about what is in the vial, the site returns nothing.
Worth trusting if
- You want the price before the questions, because Vyvron prints the program rate, the rate it reverts to and the billing period on its home page.
- You want to know who is actually treating you, because Vyvron names OpenLoop as the clinical provider and says outright that it is not a medical provider or a pharmacy.
- You want to cancel by email rather than by phone call, because that is the published method and there is no fee.
Be skeptical if
- You are planning a monthly budget, because the charge repeats every four weeks, which is thirteen times a year rather than twelve.
- You want to know what was tested and by whom, because the site never uses the words sterility, potency, USP, tested or certificate of analysis.
- You want to know which pharmacy compounded your vial, because the strongest phrase published anywhere is partner pharmacies.
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Compounded
Phase 3 trials
Not confirmed
None found
Provenance
Products reviewed at Vyvron
These evidence cards classify the treatments evaluated in this review. Confirm the exact medicine and formulation proposed for your prescription with the care team.
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- Sermorelin — Peak Recovery — $189 every four weeks as a founding member, reverting to $229.
- NAD+ — Cellular Recharge — $189 every four weeks as a founding member, reverting to $229 — the same rates as sermorelin.
- Metabolism Boost — B12 + MIC — $119 every four weeks as a founding member, reverting to $145 — the figure the /programs page gives as the whole longevity program's starting price.
- Compounded semaglutide (weight management program) — $199 every four weeks as a founding member, reverting to $249. Thirteen charges a year, not twelve. Medication is included per the cancellation policy.
- Microdose program (low-dose GLP-1 combinations) — $149 every four weeks founding, reverting to $179 — though the /programs page lists this program at "Starting at $179/mo" on the same day.
Evidence
Has the molecule been tested for what it is sold for?
Each row summarizes human evidence for the molecule and the use being advertised. Results apply to the product, dose, population and outcome studied; they do not establish that this provider’s preparation or program produces the same results. Compounded drugs are not FDA-approved. Evidence for one use should not be assumed to support another.
1
Products with human evidence
For the advertised use, out of 5 products reviewed here. The evidence concerns the molecule, not Vyvron's service.
1
Registry records cited
Distinct ClinicalTrials.gov records cited across the reviewed products. Registration alone does not establish that a treatment works.
The comparison
What they claim, against what the trials show
Each claim below is quoted word for word from Vyvron’s own page. Tap a row to see the quote, the trials behind it, and why it got that verdict.
Sermorelin — Peak RecoverySermorelin · Compounded (503A)No trial supports this claim
“Sermorelin — Peak Recovery · 4 weeks · returns to $229 · $189 FOUNDING… A recovery and performance-support path… We never promise a specific product or outcome… Compounded medications are not FDA-approved and are not identical or equivalent to any FDA-approved branded medication.”
Read on the Vyvron site, September 2026
No trial for this use
What the trials show for Sermorelin
As of August 2026, a PubMed search for sermorelin filtered to the randomized-controlled-trial publication type returned 19 records, and the most recent of the 19 was published in 2005 — a study of a PEG-conjugated GHRH analog measuring growth hormone stimulation in healthy young and elderly subjects. Reading the set, every one measures growth hormone secretion, growth in children, or the response to a diagnostic challenge. None measures recovery, performance, energy, cellular health or "vitality" as an outcome in healthy adults. A parallel search of ClinicalTrials.gov for sermorelin as an intervention returned 27 studies.
Vyvron's wording is careful and its regulatory labeling is correct — the longevity page says compounded medications are not FDA-approved, and it promises no specific product or outcome. What it sells the program for is "recovery and performance support," and its programs page sells the longevity line for "energy, cellular health, and vitality." That is where the evidence runs out. Sermorelin does stimulate pituitary growth hormone release; that is a mechanism, and it is the reason the molecule existed, largely as a diagnostic agent. The most recent randomized trial in the entire literature is more than twenty years old and measured GH secretion, not how anyone felt.1,2
NAD+ — Cellular RechargeNicotinamide adenine dinucleotide (NAD+) · Compounded (503A)No trial supports this claim
“NAD+ — Cellular Recharge · 4 weeks · returns to $229 · $189 FOUNDING… A cellular-energy and vitality path. Available in more than one form depending on your provider's evaluation.”
Read on the Vyvron site, September 2026
No trial for this use
As of August 2026, a PubMed search for "nicotinamide adenine dinucleotide" in the title or abstract, combined with an injected route (subcutaneous, injection or intravenous) and filtered to the randomized-controlled-trial publication type, returned exactly one record: a 2026 placebo-controlled trial of NAD+ in heart failure caused by ischemic cardiomyopathy. Removing the route filter raises the count to 70 records, none testing an injectable preparation for the uses sold here. A parallel ClinicalTrials.gov search for NAD+ as an intervention returned 261 studies, across conditions including lupus, mild cognitive impairment, hepatitis C and pulmonary hypertension.
Vyvron makes less of a claim here than most sellers of this product do — the listing is a name, a price and one line calling it "a cellular-energy and vitality path." That restraint is worth noting. It does not change that the outcome being sold has one randomized injected-route trial behind it, in a cardiac population, and that the buyer is paying $189 every four weeks for it, rising to $229.3
Metabolism Boost — B12 + MICMethylcobalamin with methionine, inositol and choline (B12-MIC) · Compounded (503A)No trial supports this claim
“Metabolism Boost — B12 + MIC · 4 weeks · returns to $145 · $119 FOUNDING… A metabolic and energy-support path.”
Read on the Vyvron site, September 2026
No trial for this use
As of August 2026, a PubMed search for methionine, inositol and choline together, filtered to the randomized-controlled-trial publication type, returned zero records — not a weak literature, an empty one for the combination as such. Searching the term the category uses instead, lipotropic, returned six randomized trials, and ClinicalTrials.gov listed one study with lipotropic as an intervention. The three amino compounds in a MIC injection are each individually studied; the injected blend sold under this name has not been through a registered trial.
This is the least-discussed product in the category and the one with the thinnest evidence base. Vyvron's listing makes almost no claim — "a metabolic and energy-support path" is doing the work — at $119 every four weeks, rising to $145, and there is no randomized trial of the combination at all. B12 repletion in someone actually deficient is real medicine; that is not what is being sold at a flat monthly subscription price to an unselected buyer.4
Compounded semaglutide (weight management program)Semaglutide · Compounded (503A)Claim matches the trials
“What providers may prescribe through Vyvron are compounded GLP-1 medications. Compounded medications are not FDA-approved, and they are not identical or equivalent to any FDA-approved branded medication like Wegovy, Ozempic, or Zepbound.”
Read on the Vyvron site, September 2026
Phase 3 trials
What the trials show for Semaglutide
- NCT03548935 STEP 1 — Phase 3, completed, n=1,961. Tested the approved once-weekly 2.4 mg product in adults with overweight or obesity. No compounded semaglutide preparation has been through a registered trial.
The disclaimer is accurate, it is repeated in the footer of every page rather than buried on one, and it names the branded drugs it is not equivalent to — Wegovy, Ozempic and Zepbound — rather than hedging. On the GLP-1s Vyvron claims nothing the molecule's trials do not support, which makes the silence on its peptide line stand out rather than blend in.5
Microdose program (low-dose GLP-1 combinations)Semaglutide or tirzepatide, low-dose · Compounded (503A)No trial supports this claim
“A lighter, low-dose approach. Microdose combinations pair low-dose GLP-1 medication with supportive ingredients for metabolic support and energy, when clinically appropriate… A measured starting point — for those not ready for full-dose treatment.”
Read on the Vyvron site, September 2026
No trial for this use
As of August 2026, a PubMed search combining low-dose, microdose or microdosing with semaglutide, tirzepatide or GLP-1, filtered to the randomized-controlled-trial publication type, returned 22 records. Every one of the 22 concerns dose-ranging or titration within an approved therapeutic program — the low arms of trials whose purpose was to reach a therapeutic dose. None tests a deliberately sub-therapeutic maintenance regimen combined with "supportive ingredients" as a distinct treatment, which is what is sold here. The compounded combination itself is not a registered intervention anywhere.
"Microdosing" a GLP-1 is a marketing construct rather than a studied regimen. The phase 3 evidence for semaglutide and tirzepatide was generated by titrating up to a target dose and holding it; a program built on deliberately staying below that, blended with unnamed "supportive ingredients," is not the thing that was tested. Vyvron's own framing — "a measured starting point — for those not ready for full-dose treatment" — is the most defensible version of this claim, because a starting point is what the low arms of those trials actually were. It is sold as an ongoing program at $149 every four weeks.6
Dispensing chain
Who actually fills your prescription
Read the full account
Vyvron names the clinical side of its chain and none of the pharmacy side, and it is unusually direct about the distinction. Its privacy policy states: "Vyvron is a marketing and customer-acquisition platform. Telemedicine and clinical services are provided by OpenLoop Health, Inc., OpenLoop Healthcare Partners, PC, and its affiliated medical groups." Its terms add that "Vyvron LLC is a telehealth access, brand, lifecycle, and operational support platform. Vyvron is not a medical provider, pharmacy, or insurance plan." The intake form at Vyvron's start site asks the patient to agree to OpenLoop's telehealth consent by name, so the clinical entity is disclosed at the point it matters. The pharmacy is not. The strongest statements anywhere are "partner pharmacies", "a licensed pharmacy fulfills all prescriptions" and, in the privacy policy, a reference to "OpenLoop Health, Inc. and its affiliated medical groups and partner pharmacies." No pharmacy is named, no state license number is published, and there is no way for a customer holding a vial to determine who compounded it. The corporate address, 30 N Gould St, Ste N, Sheridan, Wyoming, is a registered-agent suite rather than a clinical or dispensing site.
Read on the Vyvron site, August 2026.
Quality
Third-party testing, and what is published
Describes a testing regime
Not established in this source review
Certificate of analysis readable
A readable lot report was not verified here
Read the full testing account
Nothing. Across Vyvron's entire site — every page, every legal page, every educational article — the words "USP", "sterile", "potency", "tested", "purity", "certificate of analysis", "COA", "503A", "503B" and "lot" never appear. Not vaguely, not in a footnote: they are absent from everything the site contains. What Vyvron does publish about quality is regulatory-status language — that compounded medications "are not reviewed by the FDA for safety, effectiveness, or quality" — which describes what nobody has checked rather than what anybody has. The contrast with its own /learn library is sharp, because Vyvron has written a guide on how to verify a legitimate online GLP-1 provider and another on what LegitScript certification means. Its pages carry a LegitScript seal with certificate number 50305996; LegitScript's public checker sits behind a robot check and showed no certification record in August 2026, so the seal is displayed but not confirmed.
Read on the Vyvron site, August 2026.
Licensing
Licensed to dispense, and where
Coverage
All 50 states and Washington, D.C. for provider evaluation; compounded GLP-1s in 49 states, excluding Mississippi
Read the full licensing claim
Vyvron's own FAQ: "Vyvron connects patients with licensed providers in all 50 states plus Washington, D.C. Available nationwide; in certain states, evaluation requires a scheduled video visit (AR, DC, DE, KS, MS, NM, RI, WV). Compounded GLP-1 medications are not available to Mississippi residents; Mississippi residents may be eligible for branded options only. State, medication, and pricing availability may vary and can change." Every program page repeats the Mississippi carve-out in its footer. This is licensure asserted by a company that states it holds no clinical license itself — the licenses belong to OpenLoop's affiliated medical groups and to unnamed partner pharmacies, neither of which publishes a license number through Vyvron.
Named as outside that footprint
Read on the Vyvron site, August 2026.
Regulatory
The FDA warning letter
No FDA warning letter found
We did this ourselves
What happens when you sign up with Vyvron
We went through Vyvron’s signup ourselves in August 2026: the steps, when a price first appears, and what it asks you for. We stopped at checkout, so nothing here is a prescription or a medical result.
- Read the home page. The founding rate, the rate it reverts to, the billing period and the cancellation terms are all on it before anything is asked.
- Press See If You Qualify, which opens a four-question screener.
- Say your primary goal.
- Say whether you have tried a weight-loss program before.
- Pick the state you live in.
- Give a first name, last name and email address to see your options.
- Read a results screen confirming you can begin.
- Press Start Your Evaluation, which hands you to a separate clinical intake.
- Enter your height and weight, then a target weight.
- Say your sex assigned at birth.
- Pick any symptoms that apply, or none.
- Say which of three body-composition goals is your priority.
- Say your primary reason for taking weight loss seriously.
- Read a pace screen and say whether that pace suits you.
- Optionally give an email to save your progress — this screen has a Skip For Now.
- Answer sleep quality, then sleep duration. This walk stopped there, part-way through the clinical questions.
- Vyvron prices the program on the home page before the screener, and its own copy makes that the selling point: see your price before you answer a question.
- The rate is a founding-member rate with a stated number of places and a stated rate it returns to when they are gone. Both figures are printed side by side.
- Billing is every four weeks, not monthly, and the home page says so. That is thirteen charges a year rather than twelve.
- Cancellation is by email, effective at the end of the billing cycle, with no fee — stated on the home page rather than buried in a policy.
- The home page says when you pay: "You're charged upfront, then a provider reviews your plan. If you're denied, you receive a full refund." The refund policy agrees: the first charge is taken when you complete the intake, and a full refund follows only if a provider disqualifies you for a medical reason or you cancel within 72 hours before receiving any service.
- The four-question screener takes your name and email before it shows you anything, and the clinical questions start only after that.
- The intake runs on a different site from the storefront, so the address bar changes when the clinical questions begin.
- One screen asks for an email to save your progress and offers Skip For Now beside it, which is a genuine option rather than a disguised gate.
- This walk is partial. It stopped part-way through the clinical questions, so the checkout screen was not reached and nothing here describes it.
Vyvron support
Assessment
What holds up, and what does not
- It says what it is. "Vyvron is a marketing and customer-acquisition platform" is a sentence almost nobody in this category will write about themselves.
- It names the clinical entity — OpenLoop Health, Inc. and OpenLoop Healthcare Partners, PC — in the privacy policy and again in the intake consent.
- Every program page prints "Compounded medications are not FDA-approved" next to the price, alongside the rate the founding price returns to, rather than only in a footer.
Show 3 more
- On the GLP-1s it refuses equivalence outright: compounded medications "are not identical or equivalent to any FDA-approved branded medication like Wegovy, Ozempic, or Zepbound."
- The cancellation policy confirms medication and support are included in the subscription price, and shipping is free — so the advertised figure is the whole bill.
- Prescribing genuinely requires review: the intake at Vyvron's start site is a real clinical questionnaire, and eight states are flagged as requiring a scheduled video visit.
- There is no testing disclosure at all. The site never uses the words "sterile", "potency", "USP", "tested" or "certificate of analysis".
- No pharmacy is named anywhere — only "partner pharmacies" — so a customer has no way to learn who compounded the vial they were sent.
- Sermorelin is sold at $189 every four weeks, rising to $229, as "a recovery and performance-support path." The newest randomized sermorelin trial in the literature was published in 2005 and measured growth hormone secretion.
Show 3 more
- The B12-MIC blend has no registered trial as a combination: a search for methionine, inositol and choline together among randomized trials returned zero records.
- "Microdosing" is sold as an ongoing program, but the low arms of the GLP-1 trials were a route to a therapeutic dose, not a destination.
- The listed corporate address is a registered-agent suite in Sheridan, Wyoming.
Verdict
The bottom line
Knowing Vyvron is a marketing platform tells you who to ask, and the answer is not Vyvron. Take the quality questions to the medical group it names, because its own site never uses the words sterility, potency, USP, tested or certificate of analysis once.
Opens Vyvron's website. A link is not a recommendation to take anything.
What Vyvron will tell you
Start with the good, because it is unusual and it is load-bearing for everything after.
Most telehealth brands in this category work hard to look like a clinic. Vyvron does the opposite. Its privacy policy opens by saying "Vyvron is a marketing and customer-acquisition platform. Telemedicine and clinical services are provided by OpenLoop Health, Inc., OpenLoop Healthcare Partners, PC, and its affiliated medical groups." Its terms describe it as "a telehealth access, brand, lifecycle, and operational support platform" and state flatly that "Vyvron is not a medical provider, pharmacy, or insurance plan." The footer of every page repeats it.
That matters because it is checkable. A reader who knows the treating entity is OpenLoop can go and look at OpenLoop. A reader told only that "licensed providers" are involved cannot look at anything.
The labeling is good too. The longevity page prints "Compounded medications are not FDA-approved" directly beneath the price and says plainly, "We never promise a specific product or outcome." On the weight-management side, the disclaimer goes further than most and names names: compounded medications "are not identical or equivalent to any FDA-approved branded medication like Wegovy, Ozempic, or Zepbound."
And the signup is real. The intake at Vyvron's start site is a genuine clinical questionnaire that asks the patient to accept OpenLoop's telehealth consent by name, and eight jurisdictions are flagged as requiring a scheduled video visit rather than a form alone.
Full analysis — 5 more sectionsWhat Vyvron will not tell you · Sermorelin at $229, and a literature that stopped in 2005 · The other two, and the one that has nothing at all · Microdosing, which is a marketing word · What this adds up to
What Vyvron will not tell you
Now the part that is missing, stated precisely, because a vague version of this criticism would be unfair.
Nowhere on Vyvron's site, not on a product page, a legal page or an article in its learning library, do these words appear: "USP", "sterile", "potency", "tested", "purity", "certificate of analysis", "COA", "503A", "503B", "lot".
So this is not a failure to find the testing page. There is no testing claim anywhere on the website. Vyvron does not say its preparations are third-party tested, does not name a standard, does not state a potency tolerance, and does not publish a certificate of analysis. It also never states whether its products come from a 503A pharmacy or a 503B outsourcing facility — a distinction that determines what inspection regime applies to the vial in your hand.
The only quality-adjacent language on the site is regulatory-status language: that compounded medications "are not reviewed by the FDA for safety, effectiveness, or quality." That sentence is accurate and Vyvron deserves credit for repeating it. But it describes what has not been checked. It is not a substitute for saying what has.
The gap is sharpest against Vyvron's own library. It has published a guide titled "How to verify a legitimate online GLP-1 provider" and another on what LegitScript certification means. Its pages carry a LegitScript seal under certificate id 50305996. That seal image resolves from LegitScript's CDN; LegitScript's own public checker is reCAPTCHA-gated and returned no certification record when queried, so this review reports the seal as displayed and not as confirmed — neither claimed nor denied.
Sermorelin at $229, and a literature that stopped in 2005
The longevity page sells three programs at founding rates: NAD+ and sermorelin at $189 every four weeks, each returning to $229, and a B12 + MIC blend at $119, returning to $145. The most expensive question is sermorelin.
Vyvron's listing is short: "Sermorelin — Peak Recovery … A recovery and performance-support path." Its programs page sells the whole longevity line as "[w]ellness and healthy-aging support — options like NAD+, Sermorelin, and B12-MIC — for energy, cellular health, and vitality."
Sermorelin is a growth-hormone-releasing hormone analog, the 1-29 fragment, and it does prompt the pituitary to release growth hormone. That much is real, and it is why the molecule existed: it was used largely as a diagnostic agent to test whether a pituitary could respond.
As of August 2026, a PubMed search for sermorelin filtered to the randomized-controlled-trial publication type returns 19 records. The newest was published in 2005 — a study of a PEG-conjugated GHRH analog measuring growth hormone stimulation in healthy young and elderly subjects. 1 Read the other eighteen and the pattern holds: GH response to a challenge, growth in children with GH deficiency, dose-response to a low-dose bolus. Not one measures recovery, performance, energy or vitality in healthy adults, because that is not what anyone was studying. ClinicalTrials.gov lists 27 sermorelin studies. 2
Twenty-one years is a long time for a field to produce nothing new about the thing being sold.
The other two, and the one that has nothing at all
NAD+, also $189 founding and $229 after. As of August 2026, a PubMed search for "nicotinamide adenine dinucleotide" combined with an injected route and filtered to randomized controlled trials returns exactly one record: a 2026 placebo-controlled trial in heart failure caused by ischemic cardiomyopathy. 3 Not energy, not clarity, and not healthy adults. Vyvron makes less of a claim here than most sellers do — the listing is a name, a price and "a cellular-energy and vitality path" — and that restraint is worth acknowledging. It does not change what the buyer is paying for.
B12 + MIC, $119 founding and $145 after. This is methylcobalamin with methionine, inositol and choline — the "lipotropic" blend that has circulated in weight clinics for decades. A PubMed search for methionine, inositol and choline together, filtered to randomized controlled trials, returns zero records. 4 Searching the trade term instead, lipotropic, returns six randomized trials, and ClinicalTrials.gov lists one study with lipotropic as an intervention. The individual components are each well studied; the injected combination sold under this name has never been through a registered trial.
B12 repletion in a person who is actually deficient is ordinary, effective medicine. That is not what is on sale here. What is on sale is a flat four-weekly subscription, to an unselected buyer, for "metabolic and energy support."
Microdosing, which is a marketing word
The third program is the one worth a paragraph of its own because the framing is clever.
Vyvron sells "Microdose combinations" that "pair low-dose GLP-1 medication with supportive ingredients for metabolic support and energy," positioned as "[a] measured starting point — for those not ready for full-dose treatment."
As of August 2026, a PubMed search combining low-dose, microdose or microdosing with semaglutide, tirzepatide or GLP-1, filtered to randomized controlled trials, returns 22 records. Every one of them concerns dose-ranging or titration inside a program whose purpose was to reach a therapeutic dose. The low doses in those trials were a stage, not a destination.
Which is why Vyvron's own phrasing is the most defensible version of this product: "a measured starting point" is genuinely what the low arms of those trials were. The tension is that it is sold as an ongoing subscription at $149 every four weeks, with unnamed "supportive ingredients" blended in, and that combination is not a registered intervention anywhere.
What this adds up to
Vyvron has built the disclosure layer that this category usually skips and skipped the one it usually manages. It will tell you it is a marketing company. It will name the medical group. It will label its programs compounded and not FDA-approved and decline to call its compounded GLP-1s equivalent to the branded ones. Those are real and they are not common.
Then it sells three longevity products whose combined randomized-trial support amounts to one study in heart-failure patients and a sermorelin literature that stopped in 2005, from a pharmacy it will not name, with no published word about sterility, potency or testing of any kind.
The GLP-1 side of this business rests on strong evidence and describes itself accurately. The longevity side rests on mechanism and asks $189 every four weeks for it, then $229.
Questions
Frequently asked questions
Does Vyvron say who makes its medication?
No. Vyvron names the clinical side of its chain and not the pharmacy side. Its privacy policy states that "[t]elemedicine and clinical services are provided by OpenLoop Health, Inc., OpenLoop Healthcare Partners, PC, and its affiliated medical groups," and the intake form asks you to accept OpenLoop's telehealth consent by name. On the pharmacy the site says only "partner pharmacies" and "a licensed pharmacy fulfills all prescriptions." No pharmacy is named, no license number is published, and there is no published way to find out who compounded a given vial. The corporate address, 30 N Gould St, Ste N, Sheridan, Wyoming, is a registered-agent suite.
Does Vyvron publish anything about testing its peptides?
No. Across Vyvron's whole site — every page, every legal page, every article — the words "USP", "sterile", "potency", "tested", "purity", "certificate of analysis", "COA", "503A", "503B" and "lot" never appear. So there is no testing page to find, no standard named, no potency tolerance stated, and no lot report published. The site does correctly repeat that compounded medications are "not reviewed by the FDA for safety, effectiveness, or quality" — which is a statement about what nobody has checked, not about what Vyvron has.
Is there evidence that sermorelin does what Vyvron sells it for?
For the mechanism, yes. For the outcomes, no. Sermorelin is a growth-hormone-releasing hormone analog and it does stimulate pituitary GH release — that is why it existed, largely as a diagnostic agent. As of August 2026 a PubMed search for sermorelin filtered to randomized controlled trials returns 19 records, and the newest was published in 2005: a study of a PEG-conjugated GHRH analog measuring growth hormone stimulation. Every one of the 19 measures GH secretion, growth in children, or a diagnostic response. None measures recovery, performance, energy or vitality in healthy adults. ClinicalTrials.gov lists 27 sermorelin studies. This site does not tell you what to take and does not say sermorelin is unsafe — only that the outcomes on the page have not been tested.
What about the NAD+ and B12-MIC programs?
Thinner still, in different ways. For injectable NAD+, a PubMed search in August 2026 for "nicotinamide adenine dinucleotide" with an injected route, filtered to randomized trials, returned exactly one record — a 2026 placebo-controlled trial in heart failure caused by ischemic cardiomyopathy. For B12-MIC, a search for methionine, inositol and choline together among randomized trials returned zero records; searching the trade term "lipotropic" instead returned six trials, and ClinicalTrials.gov listed one study with lipotropic as an intervention. The components of a MIC injection are each individually studied. The injected blend sold under that name has not been through a registered trial.
Is "microdosing" a GLP-1 a recognized treatment?
Not as a distinct regimen. As of August 2026, a PubMed search combining low-dose, microdose or microdosing with semaglutide, tirzepatide or GLP-1, filtered to randomized controlled trials, returns 22 records, and all 22 concern dose-ranging or titration within programs designed to reach a therapeutic dose. Low doses in those trials were a stage on the way up, not an endpoint. Vyvron's own framing — "a measured starting point — for those not ready for full-dose treatment" — is the most accurate description of what the trial evidence supports. It is sold as an ongoing subscription at $149 every four weeks, blended with "supportive ingredients" that are not named, and that combination is not a registered intervention.
Has Vyvron had an FDA warning letter?
No match was found. Neither Vyvron nor OpenLoop, its named clinical partner, appears in the 113 warning letters FDA had issued to telehealth sellers as of August 2026. Two bounds on that: those 113 letters cover the telehealth enforcement waves rather than every letter FDA has ever issued, and absence of a letter is not a clean inspection record — pharmacy inspection findings are not published the way warning letters are, and in Vyvron's case the pharmacy is not even named.
Does Vyvron serve my state?
For the evaluation, all 50 states plus Washington, D.C. For compounded GLP-1s, 49 states — Mississippi residents are excluded, and Vyvron says they "may be eligible for branded options only." Eight places require a scheduled video visit rather than a questionnaire alone: Arkansas, Delaware, Kansas, Mississippi, New Mexico, Rhode Island, West Virginia and Washington, D.C. Note whose licenses these are: Vyvron states it holds no clinical license itself, so the coverage belongs to OpenLoop's affiliated medical groups and to unnamed partner pharmacies, none of which publishes a license number through Vyvron.
Glossary
Key terms
Show definitions
- 503A compounding pharmacy
- A state-licensed pharmacy preparing a medicine against a prescription for a named patient. Compounded preparations are not FDA-approved and FDA does not review them for safety, effectiveness or quality. Vyvron never states which category its preparations come from — the terms "503A" and "503B" do not appear anywhere on its site.
- GHRH analog
- A molecule shaped like growth-hormone-releasing hormone, which prompts the pituitary to release growth hormone rather than supplying it directly. Sermorelin is the 1-29 fragment. Stimulating the axis is a mechanism; whether that produces an outcome anyone notices is a separate question the trials have to answer.
- Lipotropic injection
- An injected blend of methionine, inositol and choline, usually with vitamin B12, long used in weight clinics. The individual compounds have literatures of their own; the blend as sold has no registered randomized trial.
- Certificate of analysis
- A lot-specific laboratory report stating what was tested and what the results were. A seller describing a testing program and a seller publishing a certificate you can read are making different claims. Vyvron makes neither.
- Four-weekly billing
- A cycle of 28 days rather than a calendar month, which produces thirteen charges in a year instead of twelve. Vyvron's checkout lines state "per 4 weeks, billed every 4 weeks", while its programs page prints the same plans with a "/mo" suffix.
Compare
Others selling what Vyvron sells
Companies we have also reviewed that dispense at least one of the same compounds, ordered by how much of what they say about their products matches the trials behind them. Nothing here is a recommendation, and none of these links earns us anything.
Ranked
The lists Vyvron is on
Method
How we checked this
Non-product facts last checked August 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off Vyvron's own pages, first-hand, on the date stamped against it — never from a summary, an aggregator, or an earlier version of this review.
Trials read from the registry
Phase, status and enrollment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 6 sources
- Munafo A, Nguyen TX, Papasouliotis O, et al. (2005). Polyethylene glycol-conjugated growth hormone-releasing hormone is long acting and stimulates GH in healthy young and elderly subjects.. European journal of endocrinology 153(2):249-56. https://pubmed.ncbi.nlm.nih.gov/16061831/
- US National Library of Medicine (2026). PubMed search: sermorelin AND randomized controlled trial[pt] — 19 records, most recent 2005; and ClinicalTrials.gov search: intervention "sermorelin" — 27 studies. Both run 2026-08-07. PubMed / ClinicalTrials.gov. https://pubmed.ncbi.nlm.nih.gov/?term=sermorelin+AND+randomized+controlled+trial%5Bpt%5D
- Yu X, Xu J, Cao J (2026). Effect of Nicotinamide Adenine Dinucleotide on Heart Failure Caused by Ischemic Cardiomyopathy: A Randomized, Placebo-Controlled Trial.. American journal of cardiovascular drugs : drugs, devices, and other interventions 26(1):97-106. https://pubmed.ncbi.nlm.nih.gov/40954388/
- US National Library of Medicine (2026). PubMed search: (methionine[tiab] AND inositol[tiab] AND choline[tiab]) AND randomized controlled trial[pt] — 0 records; lipotropic[tiab] AND randomized controlled trial[pt] — 6 records. Run 2026-08-07. PubMed. https://pubmed.ncbi.nlm.nih.gov/?term=%28methionine%5Btiab%5D+AND+inositol%5Btiab%5D+AND+choline%5Btiab%5D%29+AND+randomized+controlled+trial%5Bpt%5D
- Novo Nordisk A/S (2026). STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity, NCT03548935 — phase 3, completed, enrolment 1,961. Read 2026-08-07. ClinicalTrials.gov (US National Library of Medicine). https://clinicaltrials.gov/study/NCT03548935
- US National Library of Medicine (2026). PubMed search: ("low-dose"[tiab] OR microdose[tiab] OR microdosing[tiab]) AND (semaglutide[tiab] OR tirzepatide[tiab] OR "GLP-1"[tiab]) AND randomized controlled trial[pt] — 22 records, all dose-ranging or titration within therapeutic programmes. Run 2026-08-07. PubMed. https://pubmed.ncbi.nlm.nih.gov/?term=%28%22low-dose%22%5Btiab%5D+OR+microdose%5Btiab%5D+OR+microdosing%5Btiab%5D%29+AND+%28semaglutide%5Btiab%5D+OR+tirzepatide%5Btiab%5D+OR+%22GLP-1%22%5Btiab%5D%29+AND+randomized+controlled+trial%5Bpt%5D
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.